Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Prolgolimab |
| Trade Name | |
| Synonyms | BCD-100|BCD100|BCD 100 |
| Drug Descriptions |
Prolgolimab (BCD-100) is a monoclonal antibody against PD-1, which may promote anti-tumor immune response (Annals of Oncology, Volume 30, Issue Supplement_11, December 2019, Abstract 119P, PMID: 31847708). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | 2093956-19-3 |
| NCIT ID | C170356 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BCD-145 + Prolgolimab | BCD-145 Prolgolimab | 0 | 0 |
| Bevacizumab + Cisplatin + Paclitaxel + Prolgolimab | Bevacizumab Cisplatin Paclitaxel Prolgolimab | 0 | 1 |
| Carboplatin + Pemetrexed Disodium + Prolgolimab | Carboplatin Pemetrexed Disodium Prolgolimab | 0 | 0 |
| Cisplatin + Pemetrexed Disodium + Prolgolimab | Cisplatin Pemetrexed Disodium Prolgolimab | 0 | 0 |
| Prolgolimab | Prolgolimab | 0 | 0 |